Sorrento Ties The Knot With SmartPharm, Boosting Its Covid-19 Offering
SRNE) and SmartPharm Therapeutics have now signed a merger agreement for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.” data-reactid=”12″>Sorrento Therapeutics (SRNE) and SmartPharm Therapeutics have now signed a merger agreement for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.
Shares in Sorrento rose 4% in Thursday’s after-hours trading.
As previously announced on July 24, SmartPharm equity holders will receive up to an aggregate of $19.4 million of Sorrento common stock, based on a price per share calculated in accordance with the merger agreement.
The transaction is expected to close in early September 2020, subject to customary closing conditions.
See SRNE stock analysis on TipRanks).” data-reactid=”23″>On a year-to-date basis, Sorrento shares have had a stellar journey soaring 223% sparked by investor hopes for its COVID-19 test. Last month, Sorrento inked a licensing deal with Columbia University giving it rights to COVI-TRACE, a fast, one-step diagnostic test that samples saliva and can detect the SARS-CoV-2 virus in 30 minutes. (See SRNE stock analysis on TipRanks).
Ram Selvaraju to raise the stock’s price target to $30 (174% upside potential) from $24 and reiterate a Buy rating.” data-reactid=”24″>The deal prompted H.C. Wainwright analyst Ram Selvaraju to raise the stock’s price target to $30 (174% upside potential) from $24 and reiterate a Buy rating.
“We believe that the incentive to facilitate the large-scale and indeed ubiquitous deployment of the COVI-TRACE test is extremely high and governments worldwide may seek to implement this in their respective regions,” Selvaraju told investors.
“Our current assumptions viewed in this context may be considered conservative—we utilize a $15 price per test and anticipate that roughly 56.5 million such tests could be conducted at peak annually, resulting in total sales of roughly $1 billion.”
The analyst added that the test “could conceivably be deployed at restaurants, airports, stadiums and other mass gathering areas.”
price target indicates another 147% upside potential lies ahead.” data-reactid=”28″>Overall, only one other analyst has rated the stock recently with a Buy rating, which provides Sorrento with a Moderate Buy consensus. At $27, the average analyst price target indicates another 147% upside potential lies ahead.
Australia, AstraZeneca Ink Supply Deal For Covid-19 Vaccine Candidate
JNJ’s Momenta Acquisition a Risky Move, Says Top Analyst
Inovio: Valuation and Volatility Keep This Analyst Sidelined” data-reactid=”37″>Related News:
Australia, AstraZeneca Ink Supply Deal For Covid-19 Vaccine Candidate
JNJ’s Momenta Acquisition a Risky Move, Says Top Analyst
Inovio: Valuation and Volatility Keep This Analyst Sidelined
